Treatment of bone metastasis - Focusing on drug treatment

Research output: Contribution to journalReview articlepeer-review

Abstract

Treatment of bone metastasis consists of surgical therapy, radiotherapy, and drug therapy. Although the selection of drugs is currently limited, bisphosphonates such as zoledronate improve bone-related events and hypercalcemia, and have a central role in the drug treatment of bone metastasis. In addition, zoledronate seems to have potential anti-tumor effects in a part of bone metastases from several lines of both basic researches and clinical studies, considering a new position of zoledronate in cancer treatment. Recently, denosumab, an anti-RANKL monoclonal antibody, has been approved. Prevention of bone-related events by denosumab is equivalent to or more potent than that by zoledronate for some cancers. However, evidence supporting the effectiveness of these treatment modalities is currently limited. It is necessary to arrive at a consensus the application of different modalities and selection of drugs in the treatment of bone metastasis.

Original languageEnglish
Pages (from-to)1169-1173
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume39
Issue number8
Publication statusPublished - 2012 Aug

Keywords

  • Bone metastasis
  • Denosumab
  • Zoledronate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of bone metastasis - Focusing on drug treatment'. Together they form a unique fingerprint.

Cite this